The present invention relates to a novel and improved process for preparing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid of the formula (I), to the compound of the formula (I) in crystalline form and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular, cardiopulmonary and cardiorenal disorders.

The present invention relates to substituted aromatic compounds for use in prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis, where the compound has the following formula: ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein A is C.sub.5 alkyl, C.sub.6 alkyl, C.sub.5 alkenyl, C.sub.6 alkenyl, C(O)—(CH.sub.2).sub.n—CH.sub.3 or CH(OH)—(CH.sub.2).sub.n—CH.sub.3 wherein n is 3 or 4; R.sub.1 is H, OH or F; R.sub.2 is H, OH, F or CH.sub.2—OH; R.sub.3 is H, OH, F or CH.sub.2Ph; R.sub.4 is H, OH or F; Q is 1) (CH.sub.2).sub.mC(O)OH wherein m is 1 or 2, 2) CH(CH.sub.3)C(O)OH, 3) C(CH.sub.3).sub.2C(O)OH, 4) CH(F)—C(O)OH, 5) CF.sub.2—C(O)OH, or 6) C(O)—C(O)OH.

The present invention relates to substituted aromatic compounds for use in prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis, where the compound has the following formula: ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein A is C.sub.5 alkyl, C.sub.6 alkyl, C.sub.5 alkenyl, C.sub.6 alkenyl, C(O)—(CH.sub.2).sub.n—CH.sub.3 or CH(OH)—(CH.sub.2).sub.n—CH.sub.3 wherein n is 3 or 4; R.sub.1 is H, OH or F; R.sub.2 is H, OH, F or CH.sub.2—OH; R.sub.3 is H, OH, F or CH.sub.2Ph; R.sub.4 is H, OH or F; Q is 1) (CH.sub.2).sub.mC(O)OH wherein m is 1 or 2, 2) CH(CH.sub.3)C(O)OH, 3) C(CH.sub.3).sub.2C(O)OH, 4) CH(F)—C(O)OH, 5) CF.sub.2—C(O)OH, or 6) C(O)—C(O)OH.

Process for the preparation of a compound of Formula (I): ##STR00001## the process comprising the reaction of a compound of Formula (II) with malononitrile in the presence of a base and a palladium catalyst, ##STR00002## wherein X, Y and Z, independently of each other, represent fluoro, chloro or C.sub.1-4alkyl; and L is a leaving group; with the proviso that 1 or 2 of X and Y are, independently of each other, fluoro or chloro.

Process for the preparation of a compound of Formula (I): ##STR00001## the process comprising the reaction of a compound of Formula (II) with malononitrile in the presence of a base and a palladium catalyst, ##STR00002## wherein X, Y and Z, independently of each other, represent fluoro, chloro or C.sub.1-4alkyl; and L is a leaving group; with the proviso that 1 or 2 of X and Y are, independently of each other, fluoro or chloro.

2-(4-chloro-2,6-dimethyl-phenyl)propanedinitrile.

2-(4-chloro-2,6-dimethyl-phenyl)propanedinitrile.

The invention relates to a process for preparing a compound of (III)

##STR00001## wherein X is a leaving group; and R.sup.1 is C.sub.1-C.sub.6 alkyl;
which comprises oxidative rearrangement of a compound of formula (II) or a solvate thereof

##STR00002##

Compounds of formula (III) are key intermediates in the synthesis of Bilastine.

The invention relates to a process for preparing a compound of (III)

##STR00001## wherein X is a leaving group; and R.sup.1 is C.sub.1-C.sub.6 alkyl;
which comprises oxidative rearrangement of a compound of formula (II) or a solvate thereof

##STR00002##

Compounds of formula (III) are key intermediates in the synthesis of Bilastine.

The present invention relates to a novel and improved process for preparing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid of the formula (I), to the compound of the formula (I) in crystalline form and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular, cardiopulmonary and cardiorenal disorders.